Skip to main content
HCPCS J9179 · Level II · Part B drug

HCPCS J9179: Injection, eribulin mesylate, 0.1 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J9179

Billing unit
0.1 MG
Eribulin mesylate injection
ASP payment limit
$63.972
October 2026; +6.7% vs July 2026
Practitioner MUE
50
MAI 3
OPPS status
SI K
APC 1426
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9179 is the Level II code for Injection, eribulin mesylate, 0.1 mg, billed per 0.1 MG. The Medicare Part B ASP payment limit for October 2026 is $63.972 per billing unit, up 6.7% from July 2026. The practitioner MUE allows up to 50 units per date of service (MAI 3). Under OPPS it carries status indicator K in APC 1426. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 11 NDCs to it, sold as Eribulin Mesylate, Halaven by Hikma Pharmaceuticals USA Inc., Sandoz Inc., Baxter Healthcare Corporation. No current Billing and Coding Article lists J9179, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9179 at $63.972 per 0.1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $59.979 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9179
QuarterPayment limitPerCoinsurance
October 2026$63.9720.1 MG20%
July 2026$59.9790.1 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 11 NDCs from 11 labelers to J9179. Report the NDC in the claim's drug segment and bill the number of J9179 units that equals the quantity administered divided by 0.1 MG; the last column gives units per full package.

NDCs that crosswalk to J9179
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9167-01Eribulin MesylateHikma Pharmaceuticals USA Inc.2 × 110
00781-3391-94Eribulin MesylateSandoz Inc.2 × 110
10019-0080-01Eribulin MesylateBaxter Healthcare Corporation2 × 110
39822-2080-01Eribulin MesylateXGen Pharmaceuticals DJB, Inc.2 × 110
43598-0125-11Eribulin MesylateDr. Reddy's Laboratories Inc.2 × 110
60505-6289-00Eribulin MesylateApotex Corp2 × 110
62856-0389-01HalavenEisai Inc.2 × 110
68001-0656-41Eribulin MesylateBluePoint Laboratories2 × 110
68462-0770-20Eribulin MesylateGlenmark Pharmaceuticals Inc., USA2 × 110
72603-0368-01Eribulin MesylateNorthstar RxLLC2 × 110
81298-3890-01Eribulin MesylateLong Grove Pharmaceuticals, LLC2 × 110

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9179. For practitioners the limit is 50 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9179 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services503 Date of Service Edit: ClinicalCMS Policy
Facility outpatient hospital503 Date of Service Edit: ClinicalCMS Policy
DME supplier03 Date of Service Edit: ClinicalCMS Policy

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9179 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J9179 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9179 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J9179 carries status indicator K and is assigned to APC 1426, with a published national unadjusted payment of $59.98. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for J9179 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J9179 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS J9179

What does HCPCS code J9179 describe?

J9179 is defined by CMS as "Injection, eribulin mesylate, 0.1 mg". Each billing unit represents 0.1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J9179 in October 2026?

The ASP-based payment limit is $63.972 per 0.1 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $59.979.

How many units of J9179 can be billed per day?

The practitioner Medically Unlikely Edit is 50 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "CMS Policy" as the rationale.

Which NDCs map to J9179?

The October 2026 ASP crosswalk lists 11 NDCs from 11 labelers: Eribulin Mesylate (Hikma Pharmaceuticals USA Inc.); Eribulin Mesylate (Sandoz Inc.); Eribulin Mesylate (Baxter Healthcare Corporation); Eribulin Mesylate (XGen Pharmaceuticals DJB, Inc.). For example NDC 00143-9167-01 is a 2 package equal to 10 billing units. The crosswalk's billing-units-per-package figure converts each package into J9179 units.

Does J9179 have NCCI bundling edits?

No active practitioner PTP pairs list J9179 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.